Can L-arginine manipulation reduce renal disease?

Seminars in Nephrology

Volumn 19, Issue 3, 1999, Pages 304-309

  Klahr, Saulo ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1;

ATHEROSCLEROSIS; DIABETIC NEPHROPATHY; EXPERIMENTAL MODEL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

ANIMALS; ARGININE; DIABETIC NEPHROPATHIES; GLOMERULONEPHRITIS; HUMANS; KIDNEY DISEASES; NEPHRECTOMY; NITRIC OXIDE; RATS; URETERAL OBSTRUCTION;

EID: 0032933676     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Reyes AA, Karl IE, Klahr S: Role of arginine in health and disease. Am J Physiol 267:(Renal Fluid Electrolyte Physiol 36) F331-F346, 1994
2. Klahr S: Metabolic pathways and cycles of L-arginine synthesis and utilization, in Goligorsky MS, Gross SS, eds: Nitric Oxide and the Kidney. New York, Chapman and Hall, 1997, 113-132
3. Baylis C, Harton P, Engles K: Endothelial derived relaxing factor controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol 1:875-881, 1990
4. Morrisey JJ, Klahr S: Effects of agmatine, an active metabolite of arginine metabolism, on the kidney. Nephrol Dial Transplant 11:1217-1219, 1996
5. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90:278-281, 1992
6. Klahr S: Obstructive nephropathy. Kidney Int 54:286300, 1998
7. Schreiner GF, Harris KPG, Purkerson ML, et al: Immunological aspects of acute ureteral obstruction: Immune cell infiltrate in the kidney. Kidney Int 34:487-493, 1988
8. Reyes AA, Martin D, Settle S, et al: EDRF role in renal function and blood pressure of normal rats and with obstructive nephropathy. Kidney Int 41:403-413, 1992
9. Reyes AA, Porras BH, Chasalovv F, et al: Administration of L-arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin induced nephrosis. Kidney Int 45:1346-1354, 1994
10. Klahr S, Morrissey JJ: Comparative study of ACE inhibitors and All receptor antagonists in interstitial scarring. Kidney Int 52(suppl 63):S111-S114, 1997
11. Morrissey JJ, Ishidoya S, McCracken R, et al: Nitric oxide generation ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. J Am Soc Nephrol 7:2202-2212, 1996
12. Purkerson ML, Hoffsten PE, Klahr S: Pathogenesis of the glomerulopathy associated with renal infarction in rats. Kidney Int 9:407-416, 1976
13. Reyes AA, Purkerson ML, Karl I, et al: Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 20:168-176, 1992
14. Ashab I, Peer G, Blum M, et al: Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int 47:1515-1521, 1995
15. Aiello S, Noris M, Todeschini M, et al: Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 52:171-181, 1997
16. Reyes AA, Karl IE, Kissane J, et al: L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats. J Am Soc Nephrol 4:1039-1045, 1993
17. Bank N, Aynedjian HS: Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 43:1306-1312, 1993
18. Corbett JA, Tilton RG, Chang K, et al: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556, 1992
19. DeNicola L, Blantz RC, Gabbai FB, et al: Nitric oxide and angiotensin II. Glomerular and tubular interactions. J Clin Invest 89:1248-1256, 1992
20. Waddington S, Cook HT, Reaveley D, et al: L-arginine depletion inhibits glomerular nitric oxide synthesis and exacerbates rat nephrotoxic nephritis. Kidney Int 49:1090-1096, 1996
21. Jansen A, Cook T, Taylor GM, et al: Induction of nitric oxide synthease in rat immune complex glomerulonephritis. Kidney Int 45:1215-1219, 1994
22. Goto S, Yamamoto T, Feng L, et al: Expression and localization of inducible nitric oxide synthase in anti-Thyglomerulonephritis. Am J Pathol 147:1133-1141, 1995
23. G-monomethyl-L-arginine. J Exp Med 179:651660, 1994
24. Narita I, Border WA, Ketteier M, et al: Nitric oxide mediates immunologie injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 72:17-24, 1995
25. Furusu A, Miyazaki M, Abe K, et al: Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney Int 53:1760-1768, 1998
26. Kashem A, Endoh M, Yano N, et al: Expression of inducible NOS in human glomerulonephritis: The possible source is infiltrating monocytes/macrophages. Kidney Int 50: 392-399, 1996
27. Mohaupt MG, Elzie JL, Ahn KY, et al: Differential expression and induction of mRNAs encoding two inducible nitric oxide synthases in rat kidney. Kidney Int 46:653-665, 1994
28. Kunz D, Muhl H, Walker G, et al: Two distinct signaling pathways trigger the expression of inducible nitric oxide synthase in rat renal mesangial cells. Proc Natl Acad Sei USA 91:5387-5391, 1994
29. Saura M, Lopez S, Rodriguez PM, et al: Regulation of inducible nitric oxide synthase expression in rat mesangial cells and isolated glomeruli. Kidney Int 47:500-509, 1995
30. Shultz PJ, Archer SL, Rosenberg ME: Inducible nitric oxide synthase mRNA and activity in glomerular mesangial cells. Kidney Int 46:683-689, 1994
31. Giugliano D, Marfella R, Verazzo G, et al: The vascular effects of L-arginine in humans. J Clin Invest 99:433-438, 1997
32. Lortie MJ, Novotny WF, Peterson OW, et al: Agmatine, a bioactive metabolite of arginine-production, degradation, and functional effects in the kidney of the rat. J Clin Invest 97:413420, 1996
33. Ketteler M, Border WA, Noble NA: Cytokines and Larginine in renal injury and repair. Am J Physiol 267:(Renal Fluid Electrolyte Physiol 36) F197-F207, 1994
34. Morrissey JJ, Klahr S: Agmatine activates nitric oxide synthase in endothelial cells. Proc Assoc.Am Physicians 109: 51-57, 1997
35. Klahr S, Morrissey JJ: Renal Disease: The two faces of nitric oxide. Lab Invest 72:1-3, 1995
36. Harris KPG, Yanagisawa H, Schreiner GF, et al: Evidence for two distinct and functionally important sites of enhanced thromboxane production after bilateral ureteral obstruction. Clin Sei 81:209-213, 1991
37. Klahr S: The role of L-arginine in hypertension and nephrotoxicity. Curr Opin Nephrol Hypertens 7:547-550, 1998